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Aryl hydrocarbon receptor activation during pregnancy, and
in adult nulliparous mice, delays the subsequent development
of DMBA-induced mammary tumors
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2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), the prototypic ligand for the aryl hydrocarbon receptor (AhR), promotes tumor
formation in some model systems. However, with regard to breast cancer, epidemiological and animal studies are
inconclusive as to whether exposure increases tumor incidence or may instead be protective. We have previously reported
that mice exposed to TCDD during pregnancy have impaired differentiation of mammary tissue, including decreased branching
and poor development of lobuloalveolar structures. Because normal pregnancy-induced mammary differentiation may protect
against subsequent neoplastic transformation, we hypothesized that TCDD-treated mice would be more susceptible to
chemical carcinogenesis after parturition. To test this, mice were treated with TCDD or vehicle during pregnancy. Four weeks
later, 7,12-dimethylbenz[a]anthracene (DMBA) was administered to induce mammary tumor formation. Contrary to our
hypothesis, TCDD-exposed parous mice showed a 4-week delay in tumor formation relative to controls, and they had a lower
tumor incidence throughout the 27-week time course. The same results were obtained in nulliparous mice given TCDD and
DMBA on the same schedule. We next addressed whether the delayed tumor incidence was a reflection of decreased tumor
initiation, by testing the formation of DMBA-DNA adducts and preneoplastic lesions, induction of cytochrome P450s, and cell
proliferation. None of these markers of tumor initiation differed between vehicle- and TCDD-treated animals. The expression of
CXCL12 and CXCR4 was also measured to address their possible role in tumorigenesis. Taken together, our results suggest
that AhR activation by TCDD slows the promotion of preneoplastic lesions to overt mammary tumors.

The aryl hydrocarbon receptor (AhR) is an orphan nuclear
receptor that belongs to the per-arnt-sim (PAS) family of
transcriptional regulators.1 For many years, this receptor has
been studied primarily because of its role in the toxic effects
of dioxin-like compounds, which are ubiquitous and longlived contaminants in the environment.2 Recently, however,

interest in further understanding this receptor has been bolstered by numerous reports indicating that the AhR plays a
role in normal development, carcinogenesis and cell cycle
regulation, and likely has endogenous ligands with important
biological functions.3–6 Because of such discoveries, the
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development of nontoxic analogs of known AhR ligands for
therapeutic use has begun to be explored.7–9
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is the best
characterized AhR ligand, and it affects many organ systems
and deregulates numerous cellular pathways.2,10 TCDD is also
classiﬁed as a Class 1 carcinogen by the International Agency
for Research on Cancer11 and is established as a promoter for
certain tumors including liver and skin.12,13 For breast cancer,
however, the relationship between exposure to AhR ligands and
cancer risk is unclear. There are conﬂicting reports as to
whether exposure to AhR ligands is associated with increased
incidence of mammary neoplasias, or if it may in fact protect
against breast cancer. Investigations of human populations
exposed to dioxin-like chemicals report mixed ﬁndings of
increased and decreased association with breast cancer risk,
whereas others fail to show any correlation at all.14–17
Collectively, studies conducted in rat models indicate that
susceptibility to mammary tumors likely correlates with the age
of the animal, and by extension the differentiation state of the
mammary gland, at the time of TCDD exposure. For example,
studies conducted by Safe and coworkers using mature adult
rats demonstrated that TCDD, and other AhR agonists, can
actually cause regression of existing chemical-induced
tumors.18–20 Similarly, Kociba et al.21 found reduced incidence
of spontaneous mammary tumors in a long-term feeding with
TCDD, despite increases in incidence of tumors at other locations. In contrast to the experiments wherein TCDD is administered to adult rats, other studies addressing developmental exposure to TCDD have demonstrated increased sensitivity to
mammary tumorigenesis. Speciﬁcally, Lamartiniere and coworkers have shown that prenatal exposure to TCDD, which
alters normal development of the mammary gland, increased
the incidence of 7,12-dimethylbenz[a]anthracene (DMBA)induced mammary tumors later in life.22,23 Finally, during the
neonatal and weaning period, administration of AhR agonists
may also inﬂuence subsequent development of mammary
tumors, with somewhat conﬂicting results depending on the
timing of exposure and the mixture administered.24,25
One emerging paradigm to reconcile these seemingly conﬂicting results is that the ultimate susceptibility of mammary
tissue to carcinogenic insult is dependent upon the status of
the tissue at the time of AhR activation. More speciﬁcally,
one way by which AhR ligands such as TCDD inﬂuence
mammary tumorigenesis is interfering with normal timing of
development and differentiation of the gland, such as during
fetal development.26,27 In support of this idea, Lamartiniere
and coworkers have shown that developmental exposure to
TCDD signiﬁcantly increases the relative number of terminal
end buds (TEB) compared with developed Type II lobules at
postnatal day 50.22 Because TEB are very susceptible to carcinogenic transformation, this hypothesis ﬁts well with the
observed increase in sensitivity to DMBA-induced tumorigenesis in rats exposed developmentally to TCDD.22,23
The differentiation of mammary tissue that occurs during
pregnancy represents another critical window during which
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TCDD exposure causes profound suppression of normal development. Speciﬁcally, we have shown that mice treated
with TCDD starting at the very beginning of pregnancy have
observable defects in branching as early as day 6, and
severely stunted development of lobuloalveolar structures
with concomitant suppression of milk production by the end
of pregnancy.28,29 Given that AhR activation impairs pregnancy-associated mammary gland development, we hypothesized that these defects would inﬂuence susceptibility to
tumorigenesis postpartum. The rationale for this idea is that
pregnancy-induced changes in the mammary gland may provide protection against breast cancer later in life.30–32 Although
the speciﬁc alterations responsible for this protection are not
fully understood, this protective effect is thought to result
from permanent changes in the differentiation status or fate of
the mammary cells that are induced by pregnancy.30–32
The goal of the studies presented here was to determine
whether mice treated with TCDD during pregnancy demonstrate increased susceptibility to a mammary carcinogen
administered after parturition. In other words, we considered
that our discovery that TCDD suppresses pregnancy-induced
mammary differentiation provides at least one mechanistic
explanation for the correlation between AhR-mediated perturbation of normal mammary differentiation and altered
incidence of breast cancer. Interestingly, our results showed
that AhR activation delayed tumorigenesis regardless of pregnancy status and despite the suppression of pregnancyinduced glandular development. Further exploration into the
mechanism of the delay suggested that prior AhR activation
does not reduce carcinogen-induced DNA damage and the
initiation phase of carcinogenesis. Instead, we postulate that
the fate of the mammary epithelial cells is persistently altered
by AhR activation to slow the proliferation and promotion of
initiated cells.

Material and Methods
Animals

Female CB6F1 mice were obtained from NCI Charles River.
Both parental strains (BALB/c and C57Bl/6) express the high
afﬁnity AhRb allele that confers sensitivity to TCDD.33 Animals were given food and water ad libitum and were maintained on a 12:12-hr light cycle. For experiments conducted
in pregnant animals, female mice (age 6–7 weeks) were
housed with males and checked daily for presence of vaginal
plugs. Day 0 of pregnancy was designated as the day the vaginal plug was found. All treatment was in accordance with
protocols approved by the Washington State University Institutional Care and Use Committee.
Chemicals and animal exposures

TCDD was dissolved in anisole and diluted in peanut oil to a
concentration for dosing at 10 ll/g body weight. Mice were
administered TCDD in 3 weekly doses of 10 lg/kg (on day 0
and 7) and 5 lg/kg (on day 14). Preliminary dose-response
studies indicated that 10 lg/kg TCDD on days 0 and 7 was
C 2010 UICC
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Figure 1. Tumor study design and animal treatment. Six groups of CB6F1 mice (age 6–7 weeks at the start of the experiment) were
included in this study. Pregnant mice were treated with vehicle (n ¼ 32) or TCDD (n ¼ 32) at 3 time points during pregnancy, followed by
6 weekly doses of DMBA beginning 4 weeks after the ﬁnal TCDD treatment (equal to 3 weeks after parturition). Nulliparous age-matched
mice were treated with vehicle (n ¼ 22) or TCDD (n ¼ 20) and DMBA on the same schedule as the pregnant mice. Finally, vehicle- and
with vehicle (n ¼ 20) or TCDD (n ¼ 20) during pregnancy, then given sesame oil (the vehicle control for DMBA) beginning 3 weeks
after parturition. No tumors developed in the mice that did not receive DMBA. See Methods for additional details about the TCDD
and DMBA treatments.

necessary for substantial suppression of pregnancy-induced
gland differentiation in this strain. The dose given on day 14
was decreased to speed clearance of TCDD from the body after parturition. Mice were treated every 7 days to maintain a
relatively constant body burden of TCDD throughout pregnancy; the half-life of TCDD in mice is 11 days.34 Nulliparous mice were treated under the same TCDD paradigm as
pregnant mice to serve as controls for the effect of pregnancy. Nulliparous mice were also used for some of the
mechanistic studies, due to the fact that pretreatment with
TCDD was determined to affect tumor formation equivalently in parous and nulliparous mice, and because it is logistically easier to maintain and treat nulliparous mice for tissue
collection. Vehicle control for the TCDD treatments consisted of peanut oil containing an equivalent concentration of
anisole. DMBA (Sigma, St. Louis, MO) was dissolved in sesame oil under gentle heat to a ﬁnal concentration of 5 mg/ml
(for administering 1 mg in 200 ll).35 The solution was stored
at 4 C and kept protected from light at all times. Sesame oil
was given as the vehicle control for the DMBA treatments.
Both TCDD and DMBA, and their vehicle controls, were
administered by gavage.
Tumor study
Experimental design overview. A graphic of the experimental

design is shown in Figure 1. Female mice CB6F1 mice (age
6–7 weeks) were housed with males and checked daily for
presence of vaginal plugs. Pregnant mice (n ¼ 32 per treatment group) were treated with 10 lg/kg of TCDD, or peanut
oil vehicle, on days 0 and 7 of pregnancy, and with 5 lg/kg
on day 14. Pups were removed at birth to eliminate lactation
as a potential confounding factor (dams treated with these
doses of TCDD do not lactate and their pups would not surC 2010 UICC
Int. J. Cancer: 128, 1509–1523 (2011) V

vive28). The dams received no further treatment for 4 weeks
after the ﬁnal TCDD treatment, which is equivalent to 3
weeks after parturition, to decrease the residual body burden
of TCDD and to permit the glands to regress. Following the
no exposure period, mice were treated with 1 mg DMBA per
week for 6 weeks.36 Nulliparous age-matched animals were
treated with the same doses of TCDD (n ¼ 20) or its vehicle
(n ¼ 22) and with DMBA on the same schedule as the parous
mice. Control groups of vehicle- and TCDD-treated parous
mice (n ¼ 20 per treatment group) were not given DMBA,
but instead were administered sesame oil vehicle. These nonDMBA control animals never developed palpable tumors.
Tumor assessment. Mammary tumor formation was monitored by physical palpation twice weekly, beginning 5 weeks
after the ﬁnal administration of DMBA. The location of the
tumors was recorded. Once a tumor had enough 3-dimensional structure to measure, the size was monitored weekly
using a vernier caliper. Two perpendicular diameters, termed
length (L) and width (W), were determined, with length
deﬁned as the larger of the two measurements. Volume was
calculated using the formula 4/3  p  (L/2)  (W/2)2.37
The multiplicity of tumors was determined as follows: (the
total number tumors per group)/(number of mice with
tumors in that group).
Termination. Mice were euthanized by carbon dioxide over-

dose when a tumor length reached 25 mm, or if at any time
the animal appeared uncomfortable or moribund. The tumor
study was terminated at 27 weeks after the ﬁnal DMBA
administration. At that time, greater than 90% of the mice in
each DMBA group had either developed palpable tumors or
had died of other causes. DMBA is a multisite carcinogen,
and some of the mice developed other malignancies (often
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thymoma, also ovarian, lung, etc.) that contributed to morbidity and mortality.
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Evaluation of preneoplastic lesions. Preneoplastic lesions,

including hyperplastic alveolar nodules (HAN), ductal carcinoma in situ (DCIS), and ductal hyperplasia (DH) in the
mammary whole mounts, were quantiﬁed.38,39 Additionally,
nonpreneoplastic lesions in the gland were quantiﬁed, including cystic nodules (CN), ﬁne duct hyperplasias (FDH), dense
nodules (DN), and mammary tumors. CN were deﬁned as
focal areas of dilated alveoli. DN were small highly stained
areas comprised of epithelial and stromal cells surrounded by
dense connective tissue and with a very low-mitotic index.
MT were microscopic foci of epithelial cells that proliferated
into the surrounding stroma. Samples of all types of lesions
were veriﬁed by histological sections. Lesions were identiﬁed
in a subset of mice (n ¼ 1119 per group) that were sacriﬁced within a consistent window of time relative to DMBA
administration (22 weeks after ﬁnal DMBA treatment).
Whole mounts

Mammary whole mounts were prepared as described previously.28 Brieﬂy, the fourth and ﬁfth mammary glands were
mounted onto a glass slide under weight, and ﬁxed in Carnoy’s ﬁxative. Fixed glands were transferred to 70% ethanol,
rehydrated, and stained with carmine alum. Glands were
then dehydrated, cleared with xylenes, and mounted using
Permount (Fisher Scientiﬁc, Pittsburgh, PA). Whole mounts
were examined and given a development score based on a
four-point scale. The development scores considered epithelial branching, development of lobuloalveolar units, and the
size of the structures (1 ¼ poor development, 4 ¼ excellent
development). Photographs were taken at 3.1 using a
Jenoptik ProgRes C12plus digital camera attached to a Wild
Dissecting Microscope.
Western blotting

The levels of cytochrome P450s (Cyps) 1a1 and 1b1 and of
AhR were assessed in protein extracts from mammary gland
and/or liver. Tissues were homogenized in RIPA buffer and
protease inhibitors using a Tissue Tearor (Biospec Products).
The proteins in the supernatant were quantiﬁed and boiled
in SDS-PAGE sample buffer. Protein (30 lg) was separated
on 8% acrylamide gels, and transferred to PVDF membranes.
Primary antibodies for Cyp1a1, Cyp1b1, and actin were purchased from Santa Cruz Biotech (Santa Cruz, CA), and the
primary antibody for AhR was purchased from BIOMOL
International (now Enzo Life Sciences, Plymouth Meeting,
PA). Secondary antibodies included IRDyeTM 700DX Conjugated anti-goat IgG (Li-Cor, Lincoln, NE) and HRP-conjugated anti-rabbit antibody (DakoCytomation, Glostrup, Denmark). Bands were visualized using the Li-Cor OdysseyTM
Infrared Imaging System (for IRDye reagents), or by exposure
to X-ray ﬁlm following incubation with chemiluminescent
ECL reagents (for HRP-conjugated reagents). The intensity of
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the bands was evaluated using the Li-Cor software or from
scans of X-ray ﬁlms using Quantity One (BioRad, Hercules,
CA), as appropriate for each secondary antibody conjugate.
DMBA-DNA adduct assay

Genomic DNA from homogenized mammary glands was isolated by a standard phenol–chloroform extraction method.40
DNA adducts were determined for each DNA sample using
the nuclease P1 enrichment version of the 32P-postlabeling
method as described previously.41,42 Brieﬂy, DNA samples (4
lg) were digested with micrococcal nuclease (120 mU) and
calf spleen phosphodiesterase (40 mU), enriched and labeled
as reported. Chromatographic conditions for thin-layer chromatography (TLC) on polyethyleneimine-cellulose (PEI-cellulose) (10 cm  20 cm; Macherey-Nagel, Düren, Germany)
were: D1, 1.0 M sodium phosphate, pH 6; D3, 3.5 M lithium-formate, 8.5 M urea, pH 3.5; D4, 0.8 M lithium chloride,
0.5 M Tris-HCl, 8.5 M urea, pH 8. After chromatography,
TLC sheets were scanned using a Packard Instant Imager
(Dowers Grove, IL) and DNA adduct levels [(RAL) relative
adduct labeling] were calculated from adduct cpm, the speciﬁc activity of [c-32P]ATP and the amount of DNA (pmol
of DNA-P) used. Results were expressed as DNA adducts/108
nucleotides.
Cell proliferation analysis

The incorporation of bromodeoxyuridine (BrdU) was used to
measure the proliferation status of mammary epithelial cells.
An intraperitoneal injection of BrdU (50 mg/kg, SigmaAldrich, St. Louis, MO) was given 1 day before sacriﬁce. Abdominal-inguinal mammary glands were formalin-ﬁxed, parafﬁn-embedded, and sliced for immunohistochemical (IHC)
analysis of BrdU incorporation. A BrdU IHC System Kit
(Calbiochem, San Diego, CA) was used to stain the BrdU
positive cells according to the manufacturer’s instructions. To
count the BrdU positive epithelial cells in each tissue slice, 10
images were generated for one slice of each gland using
QCapture Pro51 software (Qimaging, Surrey, BC, Canada)
and a Nikon microscope at magniﬁcation 400.
Real-time PCR

Quantitative real-time PCR (qRT-PCR) analyses were performed to measure mRNA levels of the chemokine CXCL12
and its receptor CXCR4 in mammary tissue and tumors.
Actin was used as an endogenous control. Total RNA was
extracted from mammary glands homogenized in TRIzol reagent (Invitrogen, Carlsbad, CA). Total RNA (1 lg) was
reverse-transcribed to single strand cDNA using HighCapacity cDNA Reverse Transcription kit [Applied Biosystems (ABI), Foster City, CA]. qRT-PCR reactions were performed using the ABI Prism 7000 Sequence Detection System. TaqMan reagents and gene expression assays were from
ABI. A 25 ll reaction mixture containing 5 ll of cDNA template, 12.5 ll TaqMan Universal PCR master mix, and 1.25
ll primer probe mixture was ampliﬁed using the following
C 2010 UICC
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thermal cycler parameters: denaturation at 95 C for 10 min,
then 40 cycles of the ampliﬁcation step (denaturation at 95 C
for 15 sec and annealing/extension at 60 C for 1 min). Raw
CT (cycle threshold) values were obtained from the ABI7000
software, and used to compare the mRNA levels between the
vehicle- and TCDD-treated groups. The fold-change between
the treatment groups was calculated by ﬁrst determining the
DCT value [DCT ¼ CT (target RNA)  CT (endogenous
control)] for each sample. The unlogged DCT (¼ 2DCT) was
then determined for each vehicle-treated animal, then normalized to 1 using the average unlogged DCT of all samples
in that group. The relative fold-change for each TCDDtreated animal was calculated by comparison with the average
of the vehicle-treated group. The unlogged DCT (¼ 2DCT)
for each animal was used for statistical analysis.
Statistics

Carcinogenesis

Tumor incidence was analyzed by Fisher’s exact test and by
ANOVA, using Tukey’s test for pairwise comparisons. Other
comparisons were made using Student’s t-test. A p-value of
0.05 was considered signiﬁcant. Statistical analyses were
performed using Prism (GraphPad Software, La Jolla, CA) or
Minitab (Minitab, State College, PA).

Results
Part 1: Effect of AhR activation on mammary gland
differentiation and tumor incidence
AhR activation suppresses pregnancy-induced differentiation
of mammary glands in CB6F1 mice. Previous studies con-

ducted in C57Bl/6 mice have demonstrated that AhR activation during pregnancy suppresses normal branching and
lobuloalveolar development in the mammary gland. The central hypothesis for this study was that this suppressed differentiation would result in increased susceptibility to mammary
tumorigenesis postpartum. Because C57Bl/6 mice are less susceptible to chemical-induced carcinogenesis than the Balb/c
strain,43 CB6F1 mice (Balb/c  C57Bl/6) were used for these
tumorigenesis studies. Therefore, the ﬁrst objective was to
demonstrate the suppressive effect of TCDD on pregnancyinduced gland differentiation in this particular mouse strain.
Impregnated mice were treated with 10 lg/kg TCDD on
days 0 and 7 of pregnancy, and with 5 lg/kg on day 14.
Mammary whole mounts were made from glands taken on
day 17 of pregnancy. As shown in Figure 2, AhR activation
decreased the normal branching that occurs during pregnancy and resulted in poor development of lobuloalveolar
structures. Development scores quantifying the amount of
differentiation in glands showed that the suppression caused
by TCDD treatment was statistically signiﬁcant (Fig. 2c). The
effects presented in Figure 2 are similar to those reported
previously in TCDD-treated C57Bl/6 mice.28,29
Prior AhR activation decreases susceptibility to DMBAinduced mammary tumorigenesis. Evidence in both humans

and rodents suggests that pregnancy may cause changes in
C 2010 UICC
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Figure 2. Mammary gland differentiation that occurs during
pregnancy is disrupted by AhR activation. Impregnated CB6F1 mice
were treated with vehicle (a; n ¼ 7) or TCDD (b; n ¼ 5) at three
times during pregnancy (10 lg/kg on day 0 and day 7, and 5 lg/kg
on day 14). Whole mounts of the abdominal mammary glands were
made on day 17 of pregnancy, ﬁxed, and stained with carmine alum.
(c) Glands were given scores that considered epithelial branching,
development of lobuloalveolar units, and the size of the structures.
Bars indicate the mean score for each treatment group (6SEM).
*p  0.05. Representative photographs of glands from vehicle-treated
(a, developmental score ¼ 4) and TCDD-treated (b, developmental
score 1.5) mice were taken at 3.1. [Color ﬁgure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]

mammary cells that reduce the probability of developing
mammary tumors later in life.32,44–46 Because TCDD suppresses differentiation of the mammary gland when given to
mice during pregnancy, we tested whether these mice would
be more susceptible to DMBA-induced tumor formation later
on. To accomplish this, mice were treated with TCDD or vehicle control during pregnancy, pups were removed at birth
and the dams remained untreated for 3 weeks post-partum.
DMBA was administered once a week for 6 weeks, and
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palpable tumors were evaluated over time. Interestingly, we
found that mice treated with TCDD during pregnancy had a
decreased tumor incidence relative to the vehicle-treated
parous animals at all times examined (Fig. 3a). Speciﬁcally,
the number of tumor-positive mice at a given time point was
decreased by an average of 17% in the TCDD-treated group
compared with the vehicle-treated group (range 9–22% lower,
depending on the week). The difference between the two
groups was highly signiﬁcant (p < 0.0001). Furthermore, the
average week of tumor onset (relative to the ﬁnal DMBA
treatment) was delayed by nearly 4 weeks in the TCDDtreated animals (Fig. 3e, parous mice, p < 0.05).
The same beneﬁcial effect of prior AhR activation was
observed in nulliparous mice treated with DMBA (Fig. 3b,
p < 0.0001). Speciﬁcally, the number of tumor-positive mice
at a given time point was decreased by an average of 18% in
the TCDD-treated group compared with the vehicle-treated
group (range 7–30% lower, depending on the week). The
average time of tumor onset was also delayed by over 3
weeks in mice with prior TCDD exposure (Fig. 3e, nulliparous mice, p ¼ 0.065).
Parity status alone does not alter tumor incidence. A separate but important consideration in these studies was the
effect of parity status on tumor incidence. Pregnancy is
hypothesized to protect against tumor development in rats
and humans, and therefore, nulliparous mice were included
in the study to serve as controls for the parous animals.
However, our results showed that a single pregnancy did not
protect against tumor development, because tumor formation
in nulliparous mice was essentially the same as for the parous
animals. In other words, there were no statistically signiﬁcant
differences in the tumor incidence curves between the vehicle-treated parous mice and the vehicle-treated nulliparous
animals (Fig. 3c; p ¼ 0.30). Neither did we observe differences between the TCDD-treated parous animals and the
TCDD-treated nulliparous mice (Fig. 3d; p ¼ 0.18).
Tumor size and multiplicity are not signiﬁcantly altered by
prior AhR activation. We next determined whether growth of

the mammary tumors was affected by prior exposure to
TCDD. It is important to emphasize that we intentionally
addressed the growth rate of tumors once they had formed.
That is, given that there was an overall delay in tumor formation in the TCDD-treated mice, the number and size of
tumors in TCDD groups were smaller at a given week following DMBA exposure. Therefore, the growth of each tumor was monitored relative to the time of initial onset in
that animal.
Tumor growth was assessed in three ways. First, we calculated the number of days between the time each tumor was
ﬁrst detectable by palpation and when it grew large enough
to measure with calipers. As shown in Figure 3f, prior TCDD
exposure caused a statistically signiﬁcant retardation of tumor
growth in the nulliparous mice, but not in parous animals.
This result is suggestive that prior AhR activation slows tu-
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mor growth in addition to the timing of tumor onset, and
that the protective effect is more pronounced in nulliparous
animals. However, for the other two methods used to evaluate tumor growth, we did not observe a difference based on
parity or TCDD pretreatment. Speciﬁcally, when we determined the volume of each tumor on days 7, 14, and 21 after
the tumor was ﬁrst large enough to measure, neither prior
exposure to TCDD nor parity status affected tumor volume
at any time point (data not shown). Likewise, the number of
tumors that formed in each affected animal was not signiﬁcantly affected by either TCDD treatment or parity (tumor
multiplicity: vehicle-parous ¼ 1.13, TCDD-parous ¼ 1.37; vehicle-nulliparous ¼ 1.53, TCDD-nulliparous ¼ 1.45).
Part 2: Effect of AhR activation on tumor initiation

Chemical carcinogenesis is considered a multistep process,
consisting of initiation, promotion, and progression. In the
next series of experiments, we addressed the hypothesis that
prior activation of the AhR speciﬁcally alters tumor initiation.
Initiation parameters examined included P450 induction and
DNA damage, carcinogen-susceptible proliferating epithelial
cells, and formation of preneoplastic lesions.
Persistent AhR activation and Cytochrome P450 induction is
unlikely at the time of carcinogen administration. In the ex-

perimental design for the tumor study, administration of the
carcinogen (DMBA) began 4 weeks after the ﬁnal treatment
with TCDD. The intent of this delay was in part to allow
time for the TCDD to be cleared and reduce/eliminate the
inﬂuence of persistent AhR activation at the time the tumors
were forming. In other words, our intent was to test whether
the fate of the mammary epithelial cells was changed by prior
AhR activation, not to examine the effect of concurrent AhR
activation on a carcinogenic insult. However, it remained
possible that the AhR was still activated 4 weeks after TCDD
treatment, such that persistent induction of P450 enzymes
could alter the biotransformation of the carcinogen DMBA.
To address AhR activation status at the time of DMBA
administration, the levels of Cyp1a1 and Cyp1b1 proteins
were measured 4 weeks after the ﬁnal treatment with TCDD,
using a cohort of mice separate from the tumor study. For
comparison, the induction of these enzymes was also determined 3 days after the ﬁnal treatment with TCDD. As
expected, Cyp1a1 and Cyp1b1 were highly induced in both
the mammary gland and liver 3 days following TCDD treatment (Fig. 4, left panels). However, in the mammary gland,
these enzymes were completely absent by 4 weeks after treatment (Fig. 4a, right panels). Similar results were observed in
the liver samples, where Cyp induction was markedly
reduced, although still detectable and statistically different (p
< 0.05), by 4 weeks post-exposure (Fig. 4b, right panels).
These results strongly support the conclusion that persistent
AhR activation, particularly in the mammary gland itself, is
not responsible for the delay in tumor formation. Furthermore, the absence of persistent induction of Cyp enzymes
C 2010 UICC
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Figure 3. Prior treatment with TCDD delays tumor formation in DMBA-treated parous and nulliparous mice. The development of mammary
tumors was monitored by physical palpation beginning 5 weeks after the ﬁnal treatment with DMBA and continued for 27 weeks. (a)
Incidence of mammary tumors in DMBA-treated parous mice (triangles) that had been treated with vehicle (open triangles, n ¼ 32) or TCDD
(ﬁlled triangles, n ¼ 32) during pregnancy. The difference between the two groups was highly signiﬁcant (p < 0.0001 as analyzed by
ANOVA using a Tukey’s test for pairwise comparisons). No tumors formed in parous control mice that were not given DMBA (vehicle group
¼ open diamonds, n ¼ 20; TCDD group ¼ X symbol, n ¼ 20). (b) Tumor incidence in DMBA-treated nulliparous mice (circles) that had
been treated with vehicle (open circles, n ¼ 22) or TCDD (ﬁlled circles, n ¼ 20) and DMBA on the same schedule as the parous mice. The
difference between the two groups was highly signiﬁcant (p < 0.0001). (c and d) The same experimental groups shown in (a) and (b) were
regraphed to demonstrate the observed lack of effect of pregnancy on subsequent tumor incidence. The incidence of mammary tumors in
DMBA-treated parous (triangles) and nulliparous mice (circles) is shown both for mice pretreated with vehicle control (c) or with TCDD (d).
Statistical comparisons showed no difference between the parous and nulliparous groups (p ¼ 0.30 for c; and p ¼ 0.18 for d). (e) Average
time of tumor onset (6SEM) relative to the ﬁnal DMBA treatment. (f) Growth rate was assessed by determining the number of days
between the time each tumor was ﬁrst detected by palpation until it grew large enough to physically measure with vernier calipers.
*p  0.05; #p ¼ 0.065.
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Figure 4. Cytochrome P450 induction is transient and returns to baseline by 4 weeks following TCDD treatment. Cyp1a1 (56 kDa) and
Cyp1b1 (57 kDa) were assessed in protein extracts from (a) mammary gland and (b) liver using Western blotting. Mice were treated with 3
weekly doses of vehicle or TCDD, as described in the Methods. Tissues were collected at two time points, including 3 days after, and 4
weeks after the ﬁnal vehicle or TCDD treatment. The positive (þ) control for Cyp1a1 is liver extract from a TCDD-treated mouse, and for
Cyp1b1 is protein from cultured mammary epithelial cells (SCp2 cells) treated with 109 M TCDD for 5 days. Actin (43 kDa) was used as a
loading control. Bar graphs in (b) illustrate the magnitude of the difference in Cyp1a1 induction present at 3 days vs. 4 weeks following
TCDD exposure. Similar results were obtained for Cyp1b1. Tissues from pregnant mice were used in the 3 day time point, and nulliparous
mice were the source of tissues taken at 4 weeks. Parity status did not substantially affect baseline Cyp expression in the liver of vehicletreated animals when proteins were compared on the same blots (14% difference, not shown). *p  0.05.

suggests that differences in DMBA metabolism are unlikely
to account for the delay in tumor formation in the mice pretreated with TCDD.
Given that TCDD treatment is known to cause rapid
degradation of the AhR, which could likewise affect the
response to DMBA, we also examined the level of AhR protein in the mammary glands. Consistent with other reports
showing diminished AhR expression in cultured cell lines,
mammary gland, and other tissues,47–50 we found that AhR
levels in the mammary gland were signiﬁcantly lower in
TCDD-treated mice when assessed 3 days following treatment (Supporting Information Fig. 1). However, AhR levels
had recovered within the 4 weeks following the ﬁnal TCDD

exposure, and there was no persistent difference in receptor
levels between the treatment groups at the time DMBA was
administered.
Inﬂuence of TCDD on DMBA-DNA adduct levels. The initiation

phase of chemical carcinogenesis begins with damage to the
DNA bases. For DMBA, metabolites of the chemical form
covalent adducts with DNA that can result in DNA mismatch and mutation. To directly test whether prior exposure
to TCDD alters the formation of these lesions, the amount of
DMBA-DNA adducts in the mammary glands was investigated by 32P-postlabeling analysis. Representative TLC autoradiographs are shown in Figure 5a. The adduct pattern
C 2010 UICC
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Figure 5. Prior activation of the AhR does not change the level of DMBA-DNA adducts in the gland or the proliferative status of mammary
epithelial cells. Nulliparous mice were treated with 3 weekly doses of vehicle or TCDD, as described in the Methods. (a and b) Four weeks
after the ﬁnal vehicle or TCDD treatment, the carcinogen DMBA was administered to initiate tumor formation. Mice were sacriﬁced 24 hr
after receiving either one dose of DMBA, or after receiving 6 weekly doses of DMBA (n ¼ 6 mice per treatment group at each time point).
The number of DNA adducts in DNA extracted from the mammary glands was determined by

32

P-postlabeling. (a) The patterns of DMBA-

DNA adducts are shown in representative TLC autoradiographs. Arrows indicate the three major adduct spots, which represent adducts
formed by DMBA bay-region diol epoxides. (b) Levels of adducts (RAL ¼ relative adduct labeling) in the vehicle- and TCDD-pretreated mice
that were subsequently given one or six doses of DMBA. (c and d) Four weeks after the ﬁnal vehicle or TCDD treatment, the proliferating
mammary epithelial cells were labeled by injecting the animals with BrdU (‘‘Baseline’’). Separate groups of vehicle- and TCDD-exposed
animals were also administered a single dose of DMBA and sacriﬁced 6 days afterward (‘‘DMBA’’) (n ¼ 7 mice for each treatment group).
BrdU positive cells in mammary gland slices were detected by immunohistochemistry. (c) Examples of tissue sections showing the BrdU
stained cells (arrows) from vehicle- and TCDD-pretreated mice following DMBA exposure. Photographs were taken at 400. ‘‘D’’ indicates a
duct, ‘‘Ad’’ indicates adipocytes. (d) Quantiﬁcation of the proliferating cells was conducted by counting the total number of BrdU stained
cells in 10 separate images from each gland. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

observed after oral administration of DMBA (in the presence
or absence of TCDD) was similar to that found in mouse
skin epidermis after topical application.41 It consisted of three
major adduct spots, which have been shown to represent
DMBA-DNA adducts formed by bay-region diol epoxides.
No DNA adducts were detected in non-DMBA control tissues (data not shown). Total DMBA-DNA adduct levels are
illustrated in Figure 5b. The level of DMBA-DNA adducts
increased in response to the number of DMBA treatments
the animals received, at around 120 and 350 adducts per 108
nucleotides after one and six DMBA doses, respectively.
However, prior treatment with TCDD did not change the
damage to the DNA bases (adducts) caused by DMBA.
Proliferation status of mammary epithelial cells at the time of
carcinogen exposure. Mammary epithelial cells that are rap-

idly proliferating may be more susceptible to damage by carC 2010 UICC
Int. J. Cancer: 128, 1509–1523 (2011) V

cinogens, as evidenced by the correlation between mammary
tumor incidence and number of proliferating cells in the
ducts and end buds.22,31,45 To test whether prior exposure to
TCDD reduced the number of proliferating mammary epithelial cells (i.e., those cells possibly most susceptible to DNA
damage and mutation), BrdU incorporation was examined by
immunohistochemistry. Mice that had been treated with 3
weekly doses of vehicle or TCDD were injected with a single
dose of BrdU 4 weeks after their ﬁnal treatment. Proliferating
cells were quantiﬁed by counting the number of cells that
stained positively for BrdU (Fig. 5c). The analysis revealed
that prior AhR activation did not diminish the number of
proliferating mammary epithelial cells 4 weeks later (Fig. 5d,
left columns, ‘‘baseline’’), which was the time at which the
DMBA was administered.
In separate groups of pretreated animals, a single dose of
DMBA was given (Fig. 5d, right columns, ‘‘DMBA’’). The
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Table 1. Incidence of preneoplastic and other mammary lesions
Average number of each lesion per animal1
PNL

Non-PNL
2

Group

DCIS/DH

HAN

All PNL

MT

FDH

DN

CN

Vehicle-parous

1.0

0.4

1.4

1.0

0.2

2.2

4.0

8.8

TCDD-parous

1.8

1.0

2.9

0.9

0.1

1.5

11.4

16.7

All lesions (average number per animal)

Vehicle-nulliparous

2.4

0.7

3.1

1.0

0.6

0.8

4.7

11.9

TCDD-nulliparous

1.2

1.9

3.1

1.1

0.2

1.1

4.5

9.9

Percentage of animals per group with each lesion type
PNL
Group

DCIS/DH

Vehicle-parous

45

Non-PNL

HAN

All PNL2

MT

FDH

DN

CN

36

54.5

55

18

64

73

TCDD-parous

63

37

73.7

47

11

58

100

Vehicle-nulliparous

64

36

54.5

55

36

55

82

TCDD-nulliparous

36

45

54.5

18

9

55

91

3
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Multiplicity of each lesion type
PNL

Non-PNL
2

Group

DCIS/DH

HAN

All PNL

MT

FDH

DN

CN

Vehicle-parous

2.2

1.0

2.5

1.9

1.0

3.5

5.5

TCDD-parous

2.9

2.8

3.9

1.8

1.2

2.6

11.4

Vehicle-nulliparous

3.8

1.8

5.6

1.9

1.6

1.6

5.8

TCDD-nulliparous

3.3

4.1

5.6

6.0

2.0

1.9

5.0

Abbreviations: DCIS: ductal carcinoma in situ; DH: ductal hyperplasia; HAN: hyperplastic alveolar nodule; PNL: preneoplastic lesion; MT: mammary
tumor; FDH: ﬁne duct hyperplasias; DN: dense nodules; CN: cystic nodules.
1
Sample size: vehicle-parous (n ¼ 11), TCDD-parous (n ¼ 19), vehicle-non-parous (n ¼ 11), TCDD-non-parous (n ¼ 11). 2DCIS, DH, and HAN are
considered preneoplastic lesions. 3Multiplicity ¼ (number of lesions per group)/(number of animals with that lesion per group).

goal was to determine if prior AhR activation dampens the
proliferative response of the mammary epithelial cells resulting from DNA damage. As expected, the DMBA treatment
itself increased the number of proliferating cells relative to
cells from mice not given DMBA (baseline); however, there
was no effect of prior treatment with TCDD. Taken together,
these results show that TCDD does not cause persistent suppression in the baseline proliferative status of mammary epithelial cells, nor in their initial proliferative response to DNA
damage.
Evaluation of preneoplastic and other microscopic lesions. In

addition to macroscopic measurable tumors, DMBA and
other carcinogens induce the formation of other lesions in
the mammary gland, some of which are preneoplasias. To
ascertain whether prior activation of the AhR inﬂuences
formation of these microscopic lesions, six types of lesions
were evaluated in mammary glands from mice in the tumor study. Speciﬁcally, these lesions included two preneoplastic lesions (HAN and DCIS/DH) and four others (CN,
FDH, DN, and MT). Table 1 shows the average number of
each type of lesion found in each animal, the percentage of
animals in each group with that lesion, and the multiplicity of each lesion type. Overall, there were no consistent

differences in the incidence of these lesions between the
different treatment groups. These results further support
the conclusion that tumor initiation is not diminished by
prior activation of the AhR, because the number of preneoplastic and other lesions in the TCDD-treated mice is
similar, and in some cases even slightly higher, than in vehicle control mice.
Part 3: Effect of TCDD treatment on CXCL12
and CXCR4 in vivo

In a recent publication by Hsu et al.,51 the authors reported
that TCDD treatment of MCF-7 cells reduced the expression
of the chemokine CXCL12 and its receptor CXCR4. This discovery may be signiﬁcant because these two factors have
been implicated in breast cancer metastasis, and a reduction
in their expression was postulated to play a role in the protective role of AhR activation in breast cancer.
To address the potential for changes in CXCL12 and
CXCR4 to contribute to the delay in tumor growth in the
DMBA model, as well as to further characterize the expression of these factors in vivo, we determined their mRNA levels using qRT-PCR. Mammary glands were collected from
mice treated with 3 weekly doses of vehicle or TCDD. In one
group of mice, CXCL12 and CXCR4 levels were examined 3
C 2010 UICC
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days after the ﬁnal treatment with vehicle or TCDD. At this
time point, both CXCL12 and CXCR4 levels were signiﬁcantly increased in the TCDD-treated animals, by twofold
and 3.5-fold, respectively (Fig. 6a). However, when we examined message levels of CXCL12 and CXCR4 after 4 weeks,
the TCDD-mediated increase did not persist (Fig. 6b). Moreover, the levels of the mRNAs in the DMBA-induced mammary tumors themselves were not found to differ between
the vehicle- and TCDD-treated groups (Fig. 6c). There was
suggestive evidence for a decrease in CXCR4 expression in
tumors from TCDD-treated mice; however, the difference
was not technically statistically signiﬁcant.

Breast cancer is among the leading killers of women worldwide,52 and there is a clear need for developing novel therapeutic options and preventative measures. One strategy that
has been proposed for treating breast cancer is the use of
selective AhR modulators (SAhRMs). The use of such compounds is based on the fact that AhR is expressed in mammary cells and that AhR activation antagonizes estrogen receptor (ER) signaling and inhibits tumor growth.8,18–21
Additionally, new evidence suggests that SAhRMs may also
be effective in treating ER-negative tumors.9 The goal of the
current studies was to test whether AhR activation during
pregnancy affects susceptibility to a genotoxic mammary carcinogen administered weeks later. Interestingly, we found that
prior exposure to TCDD delayed tumor onset and reduced tumor incidence in adult mice. Furthermore, this beneﬁcial effect
of AhR activation occurred regardless of whether TCDD was
given during pregnancy or to nulliparous animals. These interesting results provide additional support and insight for a protective role of AhR activation in mammary tumorigenesis.
In our studies, TCDD was administered 4 weeks before the
animals were given DMBA and 14 weeks had elapsed by the
time the ﬁrst tumors formed. Therefore, it was important to consider whether the beneﬁcial effects resulted from persistent levels
of TCDD in the body or from persistent changes in the fate of
the mammary cells caused by previous AhR activation. To
address this, we examined the level of Cyp1a1 and Cyp1b1,
which are sensitive and commonly used biomarkers of AhR activation. Our results showed that Cyp expression in the mammary
gland itself had returned to background levels within the 4 weeks
following TCDD treatment. Given that only minute amounts of
TCDD are needed to induce Cyp1a1 and Cyp1b1,53 our results
do not support the idea that residual TCDD is directly affecting
tumor growth in our studies. Further support for this interpretation is provided by knowledge that the half-life of TCDD in
AhRb mice is 7–10 days,54,55 so the majority of the TCDD was
cleared before the growth phase of the tumors. Therefore, we
speculate that the protection afforded by prior AhR activation
results from a change in the fate of the mammary epithelial cells
that causes resistance to neoplastic transformation.
Although numerous studies have shown that AhR activation is protective against mammary carcinogenesis, the
C 2010 UICC
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Figure 6. Effect of TCDD on CXCL12 and CXCR4 expression. Parous
mice were treated with 3 weekly doses of vehicle or TCDD, as
described in the Methods. CXCL12 and CXCR4 expression were
analyzed by qRT-PCR using RNA isolated from mammary glands of
mice (n ¼ 5–6) sacriﬁced either 3 days (a), or 4 weeks (b), after
the ﬁnal TCDD treatment. (c) mRNA isolated from mammary tumors
collected during the tumor study shown in Figure 3 (n ¼ 4) were
also analyzed. *p  0.05 and a fold-change of 2 relative to
vehicle [The decrease in CXCL12 expression in (b) is technically
statistically signiﬁcant, but is substantially less than twofold. The
p value for the decrease in CXCR4 expression in (c) is 0.07.].
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precise mechanism of the protection remains unclear. We
began our investigation into the mechanism of delayed tumor
formation by examining the impact of prior AhR activation
on the initiation stage of carcinogenesis. Speciﬁcally, we
examined whether mice treated with TCDD 4 weeks prior
had (i) persistent induction of metabolic enzymes that biotransform DMBA, (ii) decreased numbers of DMBA-DNA
adducts, or (iii) diminished proliferation status of the mammary epithelial cells at the time of carcinogen administration.
We also compared (iv) the levels of preneoplastic lesions in
the mammary glands of the TCDD- and vehicle-exposed animals. Each of these four markers relevant to tumor initiation
was equivalent in mice from both treatment groups, suggesting that DNA damage and tumor initiation were not diminished by prior exposure to the AhR agonist. Taken together,
these data strongly suggest that prior AhR activation is not
altering tumor initiation in this model.
Instead, we speculate that prior AhR activation is interfering with the second stage of chemical carcinogenesis, tumor
promotion. This is supported by the ﬁndings that the level of
DMBA-DNA adducts and the incidence of preneoplastic
lesions was the same in the TCDD- and vehicle-treated mice,
yet the ultimate development of palpable tumors was suppressed in TCDD-exposed animals. TCDD is known to inﬂuence tumor promotion in other models and is in fact established as a tumor promoter in skin and liver.4,56,57 Although
these opposite effects in different tissues may at ﬁrst appear
to be irreconcilable, it is plausible that they reﬂect cell- and
context-dependent differences in AhR-mediated effects on
cell cycle regulation and apoptosis. For example, AhR activation is known to inﬂuence cell proliferation and apoptosis in
many cell lines and tissues; however, the precise nature of
the effects (increased vs. decreased) vary depending on the
cell as well as by the treatment conditions.12,13,58–61 Thus, in
summary, because the TCDD-exposed mice in our studies
had a longer latency period and decreased mammary tumor
incidence at any given time point, it is more logical that
TCDD decreases promotion in this model. Furthermore
AhR-mediated suppression, or even reversal, of tumor promotion is a reasonable explanation for the regression of preexisting mammary tumors reported previously.18–20
Although many studies in rodents show that AhR activation reduces mammary tumor growth, the complex relationship between mammary tumorigenesis, constitutive expression and function of AhR in tumors, and activation of the
receptor by exogenous ligands is not fully elucidated. Studies
conducted by Sherr and coworkers demonstrate that AhR is
overexpressed in mammary glands and tumors from DMBAtreated animals,62,63 and the receptor is also detected in
many breast cancer cell lines and human tumors.64–67 Endogenous expression and activation of AhR in mammary tumors
likely inﬂuences cell cycle regulation, and may promote tumor growth by stimulating cell proliferation and inhibiting
apoptosis.68,69 On the other hand, AhR activation with
TCDD and SAhRMs typically inhibits breast cancer cell
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growth in rodent models. This may be explained, at least for
ERþ cancer cells, by crosstalk between AhR and ER. For
example, exogenous AhR activation perturbs the expression or
function of numerous genes that inﬂuence proliferation of
breast cancer cells, including c-fos, TGF-b, TGF-a, and receptors for progesterone, prolactin, and estrogen (reviewed in Ref.
70). Mechanisms for this antiestrogenic activity may include
competition between activated AhR and ER for shared cofactors, binding of AhR to inhibitory response elements in promoter regions of ER-inducible genes, or AhR-enhanced proteosomal degradation of the ER.70–72 In future studies, we will
examine the status of AhR, hormone receptors, oncogenes,
and other modulators that inﬂuence growth of cancer cells.
This will require collecting lesions and tumors from vehicle
and TCDD pretreated mice systematically throughout the
course of tumor growth, and it is part of our ongoing investigation into the underlying molecular pathways that are disrupted by prior TCDD treatment to delay tumor onset.
A separate issue raised by these studies is unrelated to the
effect of AhR activation; speciﬁcally, the observation that
pregnancy alone did not protect against tumor formation. In
other words, the tumor incidence curve for the vehicletreated parous mice was not different from that of the vehicle-treated nulliparous animals. Nor was there a difference in
tumor formation between the TCDD-parous and TCDD-nulliparous mice. This ﬁnding was somewhat surprising, because
pregnancy is hypothesized to protect against breast cancer in
humans and has been demonstrated in rat models.30–32 However, we are aware of only one report that has directly
addressed the protective effect of pregnancy in an analogous
chemical carcinogen-treated mouse model. Speciﬁcally, Medina
and Smith46 found that pregnancy plus lactation reduced the
incidence of DMBA-induced tumors by approximately threefold and lengthened the latency period by 10 weeks. Although
our current study did not show evidence of protection provided by pregnancy, differences in the experimental designs
may explain the different outcomes. Speciﬁcally, in the Medina
and Smith study the dams nursed their pups for 1 week,
whereas in this study, we removed the pups at birth. Given
that lactation is thought to further reduce the incidence of
mammary tumors above pregnancy alone,73 it is highly probable that this explains the differing outcomes in the two studies.
Our results also provide insight into understanding the
mechanism of protection against breast cancer afforded by
pregnancy. Speciﬁcally, we found that mammary cell differentiation alone, at least differentiation that contributes to
branching and lobuloalveolar development, is not likely a
causal factor in parity-induced protection against tumor formation. In this model, AhR activation during pregnancy dramatically suppressed branching, lobuloalveolar development,
and milk production (Fig. 2 and Refs. 28 and 29). However,
suppressed glandular development did not correlate with
increased risk of developing mammary tumors, which suggests that additional factors other than differentiation must
play a role.
C 2010 UICC
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The chemokine CXCL12 and its receptor CXCR4 are
known to function in leukocyte migration to inﬂammatory
sites.74 With regard to tumorigenesis, CXCR4 is often overexpressed in human cancers, and CXCL12 may also play a
role in survival, proliferation or angiogenesis in the primary
tumor.75,76 Additionally, they are believed to play a role in
directing the migration of cancer cells to secondary metastatic sites.77 Hsu et al.51 recently reported that TCDD treatment reduced the expression of these factors in MCF-7 cells,
and postulated that this may contribute to the protective
effect of AhR activation in breast cancer. A subsequent
report by Hall et al. described similar suppression of
CXCR4 by TCDD in additional ERþ and ER breast cancer cell lines.67 In our studies, TCDD treatment caused a
transient increase in the expression of both molecules in the
mammary gland. The cause of this increase in the absence
of antigen challenge is unclear, although it could reﬂect an
enhanced inﬂammatory response that is commonly observed
in TCDD-treated animals.78–80 Regardless, this increase was
transient and did not persist at the time of carcinogen
administration. There was suggestive evidence that CXCR4
expression was diminished in tumors from the TCDDtreated mice, which would be consistent with observations
by Hsu et al. and Hall et al. in the cultured tumor cells.
However, the decrease was not technically statistically signiﬁcant. Taken together our results do not provide strong
support for a link between delayed tumor formation and
changes in CXCL12 or CXCR4, although the potential for
these molecules to inﬂuence continued tumor growth or
metastasis warrants further exploration.
As discussed previously, Lamartiniere and coworkers have
demonstrated that developmental exposure to TCDD alters
gland development and also increases susceptibility to mammary tumorigenesis.22,23 Thus, it is reasonable that the differentiation state of cells in the mammary gland at the time of
AhR activation will inﬂuence susceptibility to neoplastic
transformation. Our original intention was to test whether
the AhR-mediated suppression of normal pregnancy-induced

mammary differentiation would likewise increase susceptibility to tumor development. However, our results did not support this hypothesis for glandular differentiation caused by
pregnancy. We did not ﬁnd that altered glandular development caused by TCDD inﬂuenced the development of
DMBA-induced tumors; tumor development was delayed by
TCDD treatment regardless of whether the animal was pregnant or not at the time of exposure.
In summary, our results show that AhR activation causes
a persistent change in mammary cells that delays tumor formation, and add to the growing number of studies that have
demonstrated that AhR activation reduces mammary tumor
incidence or causes regression of existing tumors. In combination with other ﬁndings such as overexpression of AhR in
mammary tumors,62,63,68 effects of AhR activation on cell cycle
regulation and invasiveness of breast cancer cells,67,81 and the
discovery that a metabolite of tamoxifen activates AhR,82 this
report underscores the importance of understanding the role
of the receptor in breast cancer. We hypothesize that the beneﬁcial effect observed in our studies occurs via inhibiting tumor
promotion, speciﬁcally by slowing the growth of preneoplastic
lesions and initial tumors. This is promising because it provides an opportunity for biologic intervention in situations
where initiation has already occurred, and provides tantalizing
evidence to support continued exploration into the use of
SAhRMs in breast cancer treatment and prevention.
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